Icon

Fycompa - (2,4,6,8,10,12 mg; Tablet, Oral)

Perampanel EISAI INC
2,4,6,8,10,12 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older
Yes
Fycompa Patent 1 Patent 2
**** **** *** *** *********
****** (*****) **** *** *** *********
*** (****) **** *** *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ *** -**- *** ********* ********* ******** ****** **** ********
****** (*****) *** \ *** -**- *** ********* ********* ******** ****** **** ********
*** (****) ** \ ** -**- *** ********* ********* ******** ***** ***-**** ***********
  1. *** **, **** : * **** ** ** ***** *** ***** *** *** *** *********.
  2. *** **, **** : **** *** ********* ******** *** ******* *******. ********* ** ******** ****** **** ***** * **** ** ** '*** ******, *** *** ********* *** **** ****** *** **** **** ***** * **** *** ** ****** '*** (**** *, ****). *.* ***** ******** ***'* ** ******* ***** ****** ** '*** ******
  3. *** **, **** : ****** *** ********* ******** *** ******* *******. ********* ** ******** ****** ****** ***** * **** ** ** '*** ******, *** *** ********* *** **** ****** *** ****** **** ***** * **** *** ** ****** '*** (**** *, ****). *.* ***** ******** ***'* ** ******* ***** ****** ** '*** ******
  4. *** **, **** : **** *** ********* ******** *** ******* *******
  5. *** **, **** : *** (****) ******** ********* ******** *** *** *** *********. ** ****** **** **** *** ***** ********, **** ***** * **** *** ** '*** *** * **** ** ** '***.
  6. *** **, **** : *** ******** ******** ** *** **** ** ****** **** ****** '*** (**** *, ****). ** ****** **** ***** * **** *** ** '***.
  7. *** *, **** : ******** **** *** **** ************ ** ****** '*** (**** *, ****).
  8. *** **, **** : ******** *** *** **** ******* (******* *****) ********** **** ************ ** ****** '***.

Fycompa - (0.5 mg/mL ; Oral Suspension)

Perampanel EISAI INC
0.5 mg/mL ; Oral Suspension
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated as adjunctive therapy for the treatment of: 1)Partial-Onset Seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older 2)Primary Generalized Tonic-Clonic Seizures in patients with epilepsy 12 years of age and older
Yes
Fycompa Patent 1 Patent 2
*** **** **** *** *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** **** *** \ ********* *** **, **** ******* ********* ******** ******* *** **** *** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** **, **** : *** ******** ******** ** ***** **** ** ****** **** ****** '*** (*** **, ****). ** ****** **** ***** * **** *** ** '***
  3. *** *, **** : ******** **** *** **** ************ ** ****** '*** (*** **, ****)
  4. *** **, **** : ******** *** *** **** ******* (******* *****) ********** **** ************ ** ****** '***.
  5. *** **, **** : *** *** ********* ********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.